Introduction
MicroRNAs (miRNAs) are a class of single-stranded non-coding RNAs that average 22 nucleotides in length. They regulate gene expression by binding to imperfectly matched sequences in the 3'-untranslated region (3'UTR) of target mRNAs, resulting in either translational repression or destabilization/degradation of their target mRNAs [1] [2] [3] [4] [5] [6] [7] . miRNAs play an important role in nearly all cancer types, where they modulate key tumorigenesis processes, such as metastasis, apoptosis, proliferation, and angiogenesis. Each miRNA can affect several different mRNAs and, depending on the target, has the potential to function as an oncogene and/or tumor suppressor.
It has recently been shown that miRNAs play important roles in gliomas [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . A number of miRNAs, such as miR-21, miR-221, miR-222, miR-10b, and the miR-26a cluster 15, 19 , together with the genes cyclin-dependent kinase 4 (CDK4) and CENTG1, are upregulated in gliomas and appear to act in an oncogenic fashion. Other miRNAs, such as miR-124 8 , miR-137 8 , miR34a 12, 13 , miR-128 16 , miR-326 17 and members of the let-7 18 family, are downregulated indicating a tumor suppressive nature.
Several important target mRNAs and pathways have been identified for these oncomiRNAs and tumor suppressor miRNAs. For example, miR-34a is downregulated in glioblastomas as a result of p53 dysfunction, while restoring the expression of miR-34a 12 or miR-7 18 in glioma cells can strongly inhibit oncogenic pathways, such as Ras and Akt.
In addition to the singly transcribed miRNAs, our studies demonstrated that several miRNA clusters were shown to be deregulated in gliomas and might have an important role in the disease process. These clusters comprise the miR17 family, miR183-182, and the SC-specific clusters (miR367-302 and miR371-373), which are upregulated in gliomas. Because the massive cluster of 53 miRNAs on chromosome 14q32.31 is downregulated, it may represent the largest tumor suppressive miRNA cluster 20 . Some of these clusters, such as miR17-92, which is one of the three miRNA clusters related to the miR-17 family, reportedly have a pro-oncogenic roles in other type of cancers 21 .
We have recently shown that gliomas share miRNA expression profiles that are similar to neural precursor cells 20 . This result is in agreement with the finding that gliomas contain heterogeneous neoplastic cell populations that phenotypically resemble undifferentiated or immature glial cells.
The study of miRNAs is rapidly developing and could considerably change the current conception of glioma biology. Detecting and quantifying microRNAs in tissue and serum will soon be routinely used for tumor classification and grading as well as diagnostic and prognostic testing for gliomas. For example, high levels of miR-21, miR-182 and miR-196 as well as low expression of miR-181b and miR-106a are associated with poor overall survival in patients with malignant gliomas [22] [23] [24] , and these miRNAs might function as biomarkers of glioma progression. Furthermore, miR-195, miR-455-3p, miR-10a 25 and the miR-181 family 26 have been linked to treatment resistance, and assessing the relative expression levels of these miRNAs may assist with the design of personalized treatments.
New knowledge regarding the involvement of miRNAs in glioma biology has provided opportunities for the use of miRNAs or their inhibitors as potential candidates for the brain tumor treatments. However, such a therapeutic approach may be considerably challenging in light of several barriers in vivo, such as the blood-brain barrier 27 , which can prevent miRNAs or their antagonists from entering the brain.
MicroRNA regulation of gene expression
miRNAs regulate gene expression inhibition through several proposed mechanisms. One model suggests that there is competition between RISC and eIF4E for mRNA binding, which represses initiation. A second model has proposed that Ago recruits eIF6 and, thus, prevents the association of the 60S ribosomal subunit with the 40S preinitiation complex 28, 29 . The third model suggests that miRNAs destabilize target mRNAs by de-adenylation and subsequent decapping [30] [31] [32] [33] [34] . It was recently observed that AGO-2, mature miRNAs and translationally repressed mRNAs can accumulate in cytoplasmic processing bodies (P-bodies) 35 . These bodies are enriched with proteins involved in translational repression and in mRNA deadenylation, decapping and degradation. Thus, they might function not only in storage but also in the decay of repressed mRNAs. However, it remains to be established whether the accumulation of these proteins in P-bodies is the cause rather than the consequence of target mRNA silencing 36, 37 .
Mechanisms responsible for altered miRNA expression in gliomas
Aberrant miRNA expression and function has been frequently observed in gliomas. A number of mechanisms are responsible for altered miRNA expression in cancer:
a. Altered transcription regulation or abnormalities in miRNA processing.
For miR-7, normal pre-miRNA levels were found to be associated with reduced mature miRNA levels in glioblastomas, where it was proven that the reduction in the miR-7 processing was occurred at the pri-to pre-miRNA processing step 38 . Various members of the let-7 family are regulated post-transcriptionally during embryonic brain development, the neural differentiation of embryonic stem cells (SC) and in embryocarcinoma. In these settings, the levels of the pre-miRNAs were consistent during differentiation; however, the www.intechopen.com mature forms increased 39 . Few studies shed some light on this mechanism by showing that the let-7 targets, the RNA-binding proteins Lin28 and Lin28B, bind to the loop region of let-7 precursors, which blocks the processing of let-7 at either the Drosha or the Dicer levels 40, 41 . This Lin28-mediated degradation of let-7 likely plays a key role not only in development but also in tumorigenesis.
b. Localization of miRNAs inside or close to cancer-associated genomic regions 42, 43 .
This mechanism was suggested also for gliomas based on an array study on human glioma tumors and mouse and human glioma cell lines. The study demonstrated that the majority of the differentially expressed miRNAs were located in regions susceptible to genetic alterations in cancer 20 .
c. Epigenetic regulation of miRNA expression.
This is illustrated bychanges in chromatin structures that are induced by covalent modifications of histones and/or DNA methylation 44 . For example, the epigenetic silencing of the miR-124 loci has been observed in brain tumors 8 and precancerous lesions 45 . The epigenetic masking of miR-124 induces activation of the oncogene cyclin-dependent kinase (CDK)-6 and consequent phosphorylation of Rb, resulting in accelerated cell growth.
It has been shown that the Let-7 family is downregulated in gliomas 18 . This miRNA family is considered to be comprised of tumor suppressor miRNAs. The let-7a-3 locus is generally methylated in normal tissues, but it is hypomethylated in some types of cancers. The methylation levels of let-7a-3 correlate inversely with let-7a-3 pri-miRNA expression levels; thus, Let-7a-3 hypomethylation facilitates the epigenetic reactivation of the gene resulting in elevated expression of let-7a-3 and enhanced tumor phenotypes and oncogenic changes 39, 46 . Another example is miR-128, which is not regulated by epigenetics, but has been shown to play a role in the epigenesis of glioma SCs. Its downregulation in glioma tissue causes the elevated expression of Bmi-1, one of the polycomb group of genes that function as epigenetic silencers, which enhances cancer stem cell self-renewal through chromatin remodeling 16 .
The involvement of miRNAs in pathways that may promote gliomagenesis and tumor progression
miRNAs have been shown to act as both oncogenes or tumor suppressor genes and, thus, affect pathways that bestow nearly all hallmarks of cancer 47, 48 . These miRNAs can, in turn, promote gliomagenesis and tumor progression.
a. Sustaining proliferative signaling
For a tumor to become independent from external growth factor signals, it requires the activation of different cell proliferation and survival pathways, such as those mediated by epidermal growth factor receptor (EGFR) and Akt, which play a central role in glioblastomas. It has been demonstrated that miR-7 directly inhibits the expression of EGFR 38, 49 and its downstream effector, Raf1, and suppresses the AKT pathway by targeting upstream regulators. Indeed, transfection with "mimic" miR-7 oligonucleotides decreased viability and invasiveness and induces cell cycle arrest and apoptosis of glioblastoma cell lines 38, 49 .
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The altered regulation/activation of RAS proteins, which process signals downstream of growth receptors, plays a key role in the deregulation of multiple proliferation pathways in most types of tumors, including gliomas. Decreased levels of let-7 in gliomas correlate inversely with overexpression of RAS proteins, while restoring let-7 expression reduces the expression of RAS in glioma cell lines resulting in tumor growth inhibition in vitro and in vivo 18 . Moreover, the activation/overexpression of RAS leads to the upregulation of miR-21 in-vitro and in-vivo. Mir-21 exerts its oncogenic effect by downregulating the phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) 50 . In a number of human glioblastoma cell lines, such as T98G, A172, U87, and U251, the expression of PDCD4 protein correlates inversely with expression of miR-21. The downregulation of miR-21 in those cell lines leads to decreased proliferation, increased apoptosis, and decreased colony formation on soft agar 51 .
DNA amplification of an onco-amplicon was observed in a subset of high-grade gliomas. This onco-amplicon consists of miR26a-2 and the oncoproteins CDK4 and CENTG1, which regulate the RB1 and PI3 kinase/AKT pathways, respectively. miR-26a alone can functionally target PTEN, RB1, and MAP3K2/MEKK2 protein expression, thereby increasing AKT activation, promoting proliferation, and decreasing c-JUN N-terminal kinase-dependent apoptosis in vitro and in vivo. The overexpression of miR-26a in cells overexpressing CDK4 or CENTG1 further promotes tumor growth in vivo. Glioblastoma patients harboring this amplification display markedly decreased survival 15, 19 .
b. Evading growth suppressors
miRNAs may also affect cell proliferation by controlling cell cycle regulators. The E2Fs transcription factor family plays a pivotal role in cell cycle progression. In response to mitogenic signaling, pRB is sequentially phosphorylated by the CDK/cyclin complexes leading to activation of E2F-responsive genes to promote cell cycle progression 52 . This pathway can be inhibited by several miRNAs. For example, miR-137, and miR-124a inhibit CDK6 expression in different cancer cell lines, including gliomas 8 , where the transfection of miR-124 or miR-137 has been shown to prevent cell cycle progression in glioblastoma cell lines, which is associated with the decreased expression of CDK6 and pRB proteins 8 . miR34a, which is transcriptionally activated by p53, can target both CDK6 and cyclin D1 preventing the downstream pro-survival signaling of the cyclin/CDK pathway. Restoring the expression of the underexpressed miR-34a in glioma cell lines downregulates CDK6 protein expressions and inhibits cell proliferation. 12 The negative regulators of the cyclin/CDK pathway, such as members of the Cip/Kip family (p21, p27 and p57) and the INK4a/ARF family (p14 and p16), are regulated by several miRNAs. Upregulation of these miRNAs may inhibit these negative regulators and result in the proliferation and survival of the cells.
The miRNA clusters miR-106b-25 and miR-17-92 have anti-proliferative and pro-apoptotic activities in different tumor types through the inhibition of p21 in addition to other genes. Although they are also upregulated in gliomas 20 , their role in the inhibition of p21 or other negative regulators of cyclin/CDK remain to be elucidated. High levels of miR-221/222, which targets both p27 and p57, appear in glioblastomas. Functional studies showed that miR-221/222 prevents quiescence when elevated during growth factor deprivation and induces precocious S-phase entry, thereby triggering cell death 53 . In addition, the overexpression of these miRNAs increases glioma cell proliferation in-vitro and induces glioma growth in a subcutaneous mouse model 54 . The inhibition of miR-10b, which is strongly upregulated in gliomas, reduces glioma cell growth through cell-cycle arrest and apoptosis. These cellular responses are mediated by augmented expression of its direct targets, including p21 and CDKN2A/p16 55 .
c. Resisting cell death
In addition to the role of miR-221/222 in cell growth and cell cycle progression, it has been demonstrated that miR-221/222 directly regulates apoptosis by targeting p53-upregulatedmodulator-of-apoptosis (PUMA) in glioblastoma. PUMA binds to Bcl-2 and Bcl-XL through a BH3 domain and the exogenous expression of PUMA results in an extremely rapid and profound apoptosis 56 . Thus, the forced expression of miR-221/222 downregulates PUMA and induces cell survival, whereas the knockdown of miR-221/222 induces PUMA expression and cell apoptosis as well as decreases tumor growth in a xenograft model 57 .
d. Inducing angiogenesis
Recent studies have revealed important roles for miRNAs such as the endothelial cell (EC)-restricted miRNA miR-126 as well as miR-378, miR-296, miR-92a and the miR-17-92 cluster in regulating angiogenesis. Thus, these have been termed angiomirs 58 .
The level of the angiomir miR-296, which inhibits the degradation of the VEGF receptor, is increased in EC cells co-cultured with glioma cells or in response to angiogenic growth factors (including VEGF). When miR-296 is inhibited in vivo, the vascularization of tumor xenografts decreases 59 . miR-93, one of the miRNAs within the miR-106b-25 cluster, a member of the miR-17 family, enhances cell survival, promotes sphere formation and augments tumor growth. In vivo studies revealed that miR-93-expressing cells induced blood vessel formation, likely through targeting integrin-β8, allowing blood vessels to extend to tumor tissues in high densities. These findings show that miR-93 promotes tumor growth and angiogenesis through the suppression of integrin-β8 expression.
e. Activating invasion and metastasis
As mentioned above, miR-21 is overexpressed in gliomas. The metalloproteinase (MMPS) inhibitors RECK and TIMP3 are two targets of miR-21. RECK is a membrane-anchorage regulator, while TIMP3 is an extracellular matrix (ECM)-bound protease inhibitor. Treatment with antisense oligonucleotides to miR-21 in glioma cell lines and in a nude mouse model of human glioma resulted in elevated levels of RECK and TIMP3 and, therefore, reduced MMP activities. Thus, downregulation of miR-21 in glioma cells leads to a decrease in their migratory and invasion abilities 11 . miR-10b is highly expressed in many tumors, including glioblastomas. It was found that miR-10b induces glioma cell invasion by modulating the expression of the tumor invasion factors MMP-14 and uPAR through directly targeting HOXD10. Accordingly, glioma cells lost their invasive ability when they were treated with specific antisense oligonucleotides to miR-10b.
Not surprisingly, additional miRNAs are currently being identified and associated with ECM reorganization in relationship to cancer. Like miR-21 and 10b, miR-146b has also been demonstrated to play a role in glioma cell invasion 60 . However, miR-146b does not function through the suppression of ECM inhibitors; rather, its loss in gliomas allows the upregulation of MMP16, which might cause proteolysis of ECM components, such as type III collagen. Thus, low levels of miR-146b contribute to the migration and invasion of glioma 60 .
f. Reprogramming energy metabolism
Pyruvate kinase type M2 (PKM2) is one of four isoenzymes of pyruvate kinase, which catalyzes the last step within glycolysis. This enzyme is normally thought to be embryonically restricted; however, it has been shown to be expressed in cancerous cells 61 . Recently, it was shown that the levels of PKM2 negatively correlate with the levels of miR-326, suggesting a regulatory relationship between PKM2 and miR-326. Furthermore, miR-326 decreased the glioma metabolic activity by decreasing ATP levels, suggesting that miR-326 could regulate glioma metabolism through the downregulation of PKM2 62 .
The glioma microRNA expression signature
Differential miRNA expression in gliomas was first reported by Ciafre`6 3 and Chan 64 . Their study revealed that miR-21 64 and miR-221 are upregulated, whereas miR-128, miR-181a, miR-181b and miR-181c are downregulated, in glioblastoma 63 . Other array-based approaches identified that the expression of miR-124, miR-128a, and miR-137 are decreased in anaplastic astrocytomas and glioblastomas 8 . In addition, miR-124 is decreased in oligodendroglial tumors 65 relative to non-neoplastic control brain tissues.
The expression levels of miR-124 and miR-137 were increased during the differentiation of mouse neural progenitor cells (NPCs) following growth factor withdrawal. Thus, the authors have suggested that these specific miRNAs display "stemness" of glioma cells and that alteration of the levels of these miRNAs may induce differentiation 8 .
While these studies compared microRNA expression in gliomas relative to control tissues, other studies explored the role of miRNAs in glioma progression. One study investigated miRNA expression profiles in primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas. They identified 12 miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) that were upregulated and two miRNAs (miR-184 and miR-328) that were downregulated upon glioma progression 66 . Other studies have compared the differential miRNA expression between astrocytomas and glioblastomas and revealed a 23-miRNA expression signature that can discriminate glioblastomas from anaplastic astrocytomas with an overall diagnostic accuracy of 89.7%67.
Our study compared the miRNA expression signatures of glial tumors, embryonic SCs, NPCs and normal adult brains from both human and mouse tissues. We demonstrated that all gliomas displayed NPC-like miRNA signatures. About half of the miRNAs expressed in the NPCs-glioma shared profile were clustered in seven genomic regions. These clusters comprised the miR17 family (3 clusters), miR183-182, and the SC-specific clusters miR367-302 and miR371-373, which are upregulate. They also contained the bipartite cluster of 7+46 miRNAs on chromosome 14q32.31, which is downregulated in the shared expression profile. These seven regions are particularly prone to genetic and/or epigenetic aberrations www.intechopen.com in different types of cancers (e.g., LOH on chromosome 14q32.31, or the amplification of chromosome 13q31.3). Together, these findings suggest that NPCs may be the originating cells in gliomas and that aberrations in critical regions might be necessary to maintain the stem cell nature of gliomas 20 .
A recent paper analyzed microRNA expression data from The Cancer Genome Atlas (TCGA) and identified five clinically and genetically distinct glioblastoma subclasses related to a different neural precursor cell types. Thus, like us they also suggested that glioblastomas can arise from neural precursor cells but emphasized that the cell of origin could arise from multiple stages of differentiation 68 .
microRNAs as biomarkers for the diagnosis and prognosis of gliomas
As reviewed above, a large number of recent studies have discovered that miRNAs play important regulatory roles in a variety of cellular functions in gliomas. Other papers have demonstrated that miRNAs can be used for tumor classification and grading 66, 67 in addition to the diagnosis 23 , prognosis 22, 23 and prediction of therapeutic efficacy 69, 69 of tumors. The discovery of miRNAs in the serum of cancer patients 70 opened up the exciting possibility of using miRNAs as non-invasive biomarkers. Thus, detecting and quantifying microRNAs may soon be used in routine clinical practice for diagnostic and prognostic glioma testing.
The expression levels of miR-182 22 and miR-196 23 are significant in correlation with World Health Organization glioma grading (P < 0.001). Multivariate analysis showed that the expression of both these miRNAs is a predictor of overall survival in glioblastoma patients 22, 23 . Analysis of miRNA expression data in glioblastoma patients (n = 222) derived from the TCGA dataset identified an expression signature of ten miRNAs that can predict glioblastoma (GBM) patient survival 71 . In astrocytomas, the downregulation of miR-137 has been shown to be associated with advanced clinical stages of the disease; and the low expression levels of miR-181b and miR-106a, or high expression of miR-21, are significantly associated with poor patient survival 24 . Several papers aimed to identify the miRNAs specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma. In one article, the authors established resistant variant U251R cells from a TMZ-sensitive glioblastoma cell line (U251MG) and performed miRNA microarray on both the resistant and sensitive cell lines. The results showed that miR-195, miR-455-3p and miR-10a* were the three most upregulated miRNAs in the resistant cells. When miR-195 was reduced, the resistant cells displayed a moderate cell killing effect, and the combination with TMZ strongly enhanced this effect 25 . Another article examined the correlation between the expression levels of selected microRNAs in 22 primary glioblastomas with response to concomitant therapy (e.g., chemoradiotherapy with TMZ). They found that miR-181b and miR-181c were significantly downregulated in patients who responded to concomitant therapy compared to patients with progredient disease 26 .
Over many decades, it has been shown that cell-free DNA and RNA is present in the circulation and may represent potential biomarkers. We have demonstrated that tumorspecific DNA can be detected in the serum of glioma patients and is a potentially promising tool for brain tumor diagnosis 72 . Skog et al. was the first to demonstrate that www.intechopen.com brain microvascular endothelial cells take up exosomes, which contain mRNA, miRNA, and angiogenic proteins released by glioblastoma cells. Moreover, they showed that miR-21 is more elevated in serum microvesicles from glioblastoma patients than in healthy controls 73 .
Based on their potential as prognostic and diagnostic biomarkers, circulating miRNAs are promising non-invasive tumor markers. Tumor-specific circulating miRNAs may improve cancer diagnosis and prognosis because, as described above, several promising miRNAs have already been recognized as potential biomarkers for gliomas.
The therapeutic potential of microRNAs in gliomas
With the increased understanding of the miRNA target genes, the cellular behaviors influenced by them and the ability of one microRNA, such as let-7 or miR-21, to target more than one gene or pathway provide exciting opportunities to use miRNAs or their inhibitors as potential candidates for the treatment of brain tumors.
There have been few pre-clinical and phase I/II studies that showed some success in using synthetic miRNA mimics or anti-miRNA oligonucleotides as therapeutic agents. Two of these studies demonstrated that delivery of the locked-nucleic-acid (LNA)-anti-miR in African green monkeys silences miR-122, decreases the total plasma cholesterol 74 and suppresses HCV viremia 75 with no evidence of hepatotoxicity. Another study showed that the silencing of miR-155 in a mouse inflammation model by LNA-anti-miR administration results in derepression of the C/EBP Beta isoforms and downregulation of granulocytecolony stimulating factor expression in mouse splenocytes 76 . In gliomas, the silencing of miR-21 by LNA-anti-miR followed by TRAIL treatment increased caspase activity in vitro and reduced tumor growth in vivo 10 . These results support the potential of LNA-anti-miR as therapeutics for inhibition of disease-associated miRNAs.
An alternative to chemically modified antisense oligonucleotides is the "miR sponge". These competitive miR inhibitors contain multiple binding sites to an miR of interest, preventing it from binding to its natural target. In this way, a single sponge can block all miR family members containing the same seed sequences. The sponge strategy has been used to inhibit miR-31 in vivo in a noninvasive breast cancer cell line. miR sponges that carried miR-31 recognition motifs were introduced into a retroviral vector and reduced miR-31 function significantly 77 .
Some preclinical studies have shown promising results using self-complementary adenoassociated viral (scAAV) vectors. For example, a scAAV vector containing miR-26a was administered with a single tail-vein injection into mice with established liver tumors. High miR-26a levels were found in their livers and no toxic effects were observed. While six out of eight mice treated with the control virus developed tumors, eight out of ten miR-26a-treated mice developed only small tumors or had a complete absence of tumors 78 .
Although most of these therapeutic approaches appear promising for systemic tumors, they would be considerably challenging in brain tumors due to several obstacles and barriers in vivo, such as the blood-brain barrier 27 , which might prevent the miRNAs or their antagonists from entering the brain. Thus, the development of more efficient and specific www.intechopen.com
